Complexo de inclusão entre β-ciclodextrina e acetato de hecogenina produz efeito analgésico superior em modelos animais de dor orofacial

• Autor(a) principal: Rezende, Marília Matos
• Data de Publicação: 2018
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFS
• Texto Completo: http://ri.ufs.br/jspui/handle/riufs/10705
• topic: Farmácia; Ensino de farmácia; Dor orofacial; Ciclodextrina; Acetato de hecogenina; Orofacial pain; Cyclodextrin; Hecogenin acetate; CIENCIAS DA SAUDE::FARMACIA::ANALISE E CONTROLE E MEDICAMENTOS

The treatment of pain mainly of orofacial pain and its therapeutic interventions in order to improve the quality of life and remedy the painful symptoms of the patient have been the main current problem of medicine, not only by limiting the options that There are, but also by the amount of side effects that accompany them. Therefore, the study of substances derived from natural products is a hope for the improvement of pain management. The species of plants of the genus Agave or "sisal" used in the popular medicine of the Brazilian Northeast for possessing favorable therapeutic properties, have already been used by the industry as a basis for synthesis of steroidal hormones. Previous studies have observed that hecogenin, a steroidal saponin present in this genus of plants, in the acetylated form, demonstrated anti-nociceptive and anti-inflammatory effect in animal models. In order to overcome the low aqueous solubility of HA, it has been envisaged to take advantage of the ability of cyclodextrin (CD) molecules to form inclusion complexes with non-polar substances in order to improve water solubility and hence bioavailability. Objective: To evaluate the anti-nociceptive activity of the Hecogenina acetate (HA) and the AH/β-cyclodextrin (HA-ΒCD) in orofacial pain model in rodents. Methods: Swiss male mice (25-30 g) (CEPA/UFS # 04/12) subjected to orofacial pain models induced by formalin, capsaicin and glutamate. The animals (n = 6) were treated with the HA or HA-ΒCD (20 mg/kg), or vehicle, orally. The results were considered significant when p < 0.05. Results: It was observed that the HA-ΒCD complex presented an improvement in the anti-nociceptive effect in the formalin-induced and glutamate pain model compared to the control (p < 0.01 and p < 0.001). Conclusion: With the obtained results, therefore, we observed that the HA when complexed with a β-CD showed anti-nociceptive effect in animal models of orofacial use.